SEQUANTRIX develops precision therapeutics for chronic kidney disease, heart failure, and myelofibrosis using its proprietary AI‑to‑in vivo platform, which integrates artificial intelligence with in‑vivo validation to identify and optimize disease‑modifying candidates. The platform enables the company and pharmaceutical partners to address target discovery, drug design, and preclinical testing for fibrosis‑driven conditions across multiple organs, accelerating the creation of treatments that restore tissue architecture and function.
Funding
Funding not disclosed
Founders
Product
Problem
Chronic kidney disease, heart failure, and myelofibrosis lack disease-modifying therapies that can reverse fibrosis, inflammation, and cellular injury, leading to progressive organ failure and high mortality.
Solution
Sequantrix operates an AI‑to‑in‑vivo platform that integrates computational modeling, machine‑learning predictions, and animal validation to identify precision therapeutic candidates targeting the shared pathways of fibrosis and inflammation across organs. The platform screens large molecular libraries in silico, prioritizes candidates based on predicted efficacy in restoring tubular, cardiomyocyte, or stromal cell function, and then confirms activity in vivo. By accelerating target discovery and preclinical validation, Sequantrix aims to generate disease‑modifying drugs that can regenerate damaged tissue and halt progression in chronic kidney disease, heart failure, and myelofibrosis. The company also offers the platform as a service to pharmaceutical partners seeking to explore fibrotic disease mechanisms and evaluate novel targets.
Target Audience
Primary customers are pharmaceutical companies and biotech firms developing treatments for fibrotic and inflammatory diseases, as well as research groups focused on chronic kidney disease, heart failure, and myelofibrosis.
Features
- Integrated AI pipeline that combines multi‑omics data, disease modeling, and predictive analytics to prioritize therapeutic targets
- In‑vivo validation workflow using disease‑relevant animal models for rapid efficacy assessment
- Cross‑organ capability to address fibrosis, chronic inflammation, and cellular injury in kidney, heart, and bone‑marrow contexts
- Modular platform access for external pharma partners to conduct target and drug discovery projects
- Data‑driven candidate selection focused on restoring specific cellular functions such as tubular regeneration or cardiomyocyte repair